Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy (Q37621564)

21 August 2017

1 reference

title

Tumor Necrosis Factor-related apoptosis-inducing ligand (TRAIL) Receptor-1 and Receptor-2 agonists for cancer therapy (English)

1 reference

21 August 2017

1 reference

Norma Lynn Fox

1

1 reference

21 August 2017

Robin Humphreys

2

1 reference

21 August 2017

Troy A Luster

3

1 reference

21 August 2017

Jerry Klein

4

1 reference

21 August 2017

Gilles Gallant

5

1 reference

21 August 2017

language of work or name

English

0 references

publication date

1 January 2010

1 reference

Expert Opinion on Biological Therapy

21 August 2017

1 reference

21 August 2017

10

1 reference

21 August 2017

1

1 reference

21 August 2017

1-18

1 reference

Trail receptors: targets for cancer therapy

21 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/Tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Directing cancer cells to self-destruct with pro-apoptotic receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

The TRAIL apoptotic pathway in cancer onset, progression and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

TRAIL and osteoprotegerin: a role in endothelial physiopathology?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Following TRAIL's path in the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Apoptosis: a review of programmed cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Intrinsic tumour suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Mechanisms of resistance to TRAIL-induced apoptosis in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

TRAIL receptor-targeted therapeutics: resistance mechanisms and strategies to avoid them.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Histone deacetylase inhibitors enhance lexatumumab-induced apoptosis via a p21Cip1-dependent decrease in survivin levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Proteasome inhibitors sensitize ovarian cancer cells to TRAIL induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Selective targeting of death receptor 5 circumvents resistance of MG-63 osteosarcoma cells to TRAIL-induced apoptosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Modulation of death receptors by cancer therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

FLIP and the death effector domain family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Cell surface Death Receptor signaling in normal and cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Apoptosis control by death and decoy receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Differential regulation of the TRAIL death receptors DR4 and DR5 by the signal recognition particle

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Apoptosis in hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Dengue virus-induced apoptosis in hepatic cells is partly mediated by Apo2 ligand/tumour necrosis factor-related apoptosis-inducing ligand.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Cytokines induced during chronic hepatitis B virus infection promote a pathway for NK cell-mediated liver damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Tumour necrosis factor related apoptosis inducing ligand (TRAIL) induces hepatic steatosis in viral hepatitis and after alcohol intake

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Mcl-1L cleavage is involved in TRAIL-R1- and TRAIL-R2-mediated apoptosis induced by HGS-ETR1 and HGS-ETR2 human mAbs in myeloma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Bortezomib sensitizes non-Hodgkin's lymphoma cells to apoptosis induced by antibodies to tumor necrosis factor related apoptosis-inducing ligand (TRAIL) receptors TRAIL-R1 and TRAIL-R2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Proteasome inhibitor PS-341 (VELCADE) induces stabilization of the TRAIL receptor DR5 mRNA through the 3'-untranslated region

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Death receptor-4 (DR4) expression is regulated by transcription factor NF-kappaB in response to etoposide treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Human agonistic TRAIL receptor antibodies Mapatumumab and Lexatumumab induce apoptosis in malignant mesothelioma and act synergistically with cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Enhancement of death receptor 4 mediated apoptosis and cytotoxicity in renal cell carcinoma cells by subtoxic concentrations of doxorubicin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and pharmacokinetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Mapatumumab, a fully human agonistic monoclonal antibody that targets TRAIL-R1, in combination with gemcitabine and cisplatin: a phase I study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Human agonistic antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2 induces cytotoxicity and apoptosis in prostate cancer and bladder cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Lexatumumab (TRAIL-receptor 2 mAb) induces expression of DR5 and promotes apoptosis in primary and metastatic renal cell carcinoma in a mouse orthotopic model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Cooperation of the agonistic DR5 antibody apomab with chemotherapy to inhibit orthotopic lung tumor growth and improve survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

A novel humanized anti-human death receptor 5 antibody CS-1008 induces apoptosis in tumor cells without toxicity in hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

TRA-8 anti-DR5 monoclonal antibody and gemcitabine induce apoptosis and inhibit radiologically validated orthotopic pancreatic tumor growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Combination treatment with TRA-8 anti death receptor 5 antibody and CPT-11 induces tumor regression in an orthotopic model of pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Treatment of human colon cancer xenografts with TRA-8 anti-death receptor 5 antibody alone or in combination with CPT-11.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Early therapy evaluation of combined anti-death receptor 5 antibody and gemcitabine in orthotopic pancreatic tumor xenografts by diffusion-weighted magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

High-resolution single-photon emission computed tomography and X-ray computed tomography imaging of Tc-99m-labeled anti-DR5 antibody in breast tumor xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

To kill a tumor cell: the potential of proapoptotic receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

A unique zinc-binding site revealed by a high-resolution X-ray structure of homotrimeric Apo2L/TRAIL

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Safety and antitumor activity of recombinant soluble Apo2 ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand cooperates with chemotherapy to inhibit orthotopic lung tumor growth and improve survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Elimination of hepatic metastases of colon cancer cells via p53-independent cross-talk between irinotecan and Apo2 ligand/TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Bortezomib abolishes tumor necrosis factor-related apoptosis-inducing ligand resistance via a p21-dependent mechanism in human bladder and prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

DR4-selective tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) variants obtained by structure-based design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

End points and United States Food and Drug Administration approval of oncology drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Endpoints for assessing drug activity in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Design and endpoints of clinical trials in hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Selection of response criteria for clinical trials of sarcoma treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Mcl-1: a gateway to TRAIL sensitization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

The C-terminal tails of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and Fas receptors have opposing functions in Fas-associated death domain (FADD) recruitment and can regulate agonist-specific mechanisms of receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

TRAIL signalling: decisions between life and death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Inhibition of Histone Deacetylase Class I but not Class II Is Critical for the Sensitization of Leukemic Cells to Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712590903319656

10.1517/14712590903319656

21 January 2018

Identifiers

DOI

1 reference

21 August 2017

1 reference